SPOP mutations in prostate cancer across demographically diverse patient cohorts

Neoplasia (United States)

Volumn 16, Issue 1, 2014, Pages 14-20

  Blattner, Mirjam ^a   Lee, Daniel J ^a   O'Reilly, Catherine ^a   Park, Kyung ^a   MacDonald, Theresa Y ^a   Khani, Francesca ^a   Turner, Kevin R ^a   Chiu, Ya Lin ^a   Wild, Peter J ^b   Dolgalev, Igor ^c   Heguy, Adriana ^c   Sboner, Andrea ^a   Ramazangolu, Sinan ^a   Hieronymus, Haley ^c   Sawyers, Charles ^c   Tewari, Ashutosh K ^a   Moch, Holger ^b   Yoon, Ghil Suk ^d   Known, Yong Chul ^e   Andrén, Ove ^f,g   Fall, Katja ^f   Demichelis, Francecsa ^a,h   Mosquera, Juan Miguel ^a   Robinson, Brian D ^a   Barbieri, Christopher E ^a   Rubin, Mark A ^a   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d Kyungpook National University School of Medicine   (South Korea)

^e Catholic University of Daegu   (South Korea)

^f ÖREBRO UNIVERSITY   (Sweden)

^g ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF TRENTO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; SPECKLE TYPE POZ PROTEIN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DNA EXTRACTION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GLEASON SCORE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ASSAY; SAMPLING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DNA HELICASES; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; EXONS; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, DNA; TRANS-ACTIVATORS;

EID: 84900445994     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131704     Document Type: Article

References (28)

1. Siegel R, Naishadham D, and Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin 62, 10-29.
2. Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll PR, Rubin MA, and Scardino PT (2008). Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology 72, S12-S24.
3. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648.
4. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, et al. (2006). TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66, 8337-8341.
5. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, et al. (2012). Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44, 685-689.
6. Zhuang M, Calabrese MF, Liu J, Waddell MB, Nourse A, Hammel M, Miller DJ, Walden H, Duda DM, Seyedin SN, et al. (2009). Structures of SPOPsubstrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol Cell 36, 39-50.
7. Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P, Wiklund F, Mills IG, Egevad L, and Gronberg H (2013). Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol 63, 347-353.
8. Solassol J, Ramos J, Crapez E, Saifi M, Mange A, Vianes E, Lamy PJ, Costes V, and Maudelonde T (2011). KRAS mutation detection in paired frozen and formalin-fixed paraffin-embedded (FFPE) colorectal cancer tissues. Int J Mol Sci 12, 3191-3204.
9. Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, and Pryor RJ (2003). High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 49, 853-860.
10. Ririe KM, Rasmussen RP, and Wittwer CT (1997). Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem 245, 154-160.
11. Reed GH, Kent JO, and Wittwer CT (2007). High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 8, 597-608.
12. Mortezavi A, Hermanns T, Seifert HH, Baumgartner MK, Provenzano M, Sulser T, Burger M, Montani M, Ikenberg K, Hofstadter F, et al. (2011). KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 17, 1111-1121.
13. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22.
14. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, et al. (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595-599.
15. Svensson MA, LaFargue CJ, MacDonald TY, Pflueger D, Kitabayashi N, Santa- Cruz AM, Garsha KE, Sathyanarayana UG, Riley JP, Yun CS, et al. (2011). Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest 91, 404-412.
16. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, et al. (2011). The genomic complexity of primary human prostate cancer. Nature 470, 214-220.
17. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, et al. (2010). Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12, 590-598.
18. Li H and Durbin R (2010). Fast and accurate long-read alignment with Burrows- Wheeler transform. Bioinformatics 26, 589-595.
19. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, et al. (2013). Punctuated evolution of prostate cancer genomes. Cell 153, 666-677.
20. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al. (2012). The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243.
21. Roehl KA, Han M, Ramos CG, Antenor JA, and Catalona WJ (2004). Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172, 910-914.
22. Han M, Partin AW, Piantadosi S, Epstein JI, and Walsh PC (2001). Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 166, 416-419.
23. Chun FK, Graefen M, Zacharias M, Haese A, Steuber T, Schlomm T, Walz J, Karakiewicz PI, and Huland H (2006). Anatomic radical retropubic prostatectomy- long-term recurrence-free survival rates for localized prostate cancer. World J Urol 24, 273-280.
24. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, and Murphy KM (2010). Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 12, 425-432.
25. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, et al. (2008). Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100, 815-825.
26. Khani FMJ Park K, et al. (2013). Evidence for molecular differences in prostate cancer between African American and Caucasian men. submitted for publication.
27. Ralser M, Querfurth R, Warnatz HJ, Lehrach H, Yaspo ML, and Krobitsch S (2006). An efficient and economic enhancer mix for PCR. Biochem Biophys Res Commun 347, 747-751.
28. Gonzalez-Bosquet J, Calcei J, Wei JS, Garcia-Closas M, Sherman ME, Hewitt S, Vockley J, Lissowska J, Yang HP, Khan J, et al. (2011). Detection of somatic mutations by high-resolution DNA melting (HRM) analysis in multiple cancers. PLoS One 6, e14522.